Regulatory approval was supported by a statistically significant improvement in 1‑year moderate‑to‑severe cGVHD‑free survival ...
Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL ...
Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims ...
Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors. In an interview with Targeted Oncology at the ...
Dr. Monty Pal introduces the program by outlining the evolving treatment landscape for advanced renal cell carcinoma (RCC) ...
Daniel Ermann, MD, discusses how clinical and real-world data drive his discussions with older CLL patients regarding ...
NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...
Conversion from MRD negativity to positivity during maintenance is substantially lower with the quadruplet, and ...
Daniel Ermann, MD, discusses his approach to treatment sequencing in patients with chronic lymphocytic leukemia who aged 80 ...
Daniel Ermann, MD, discusses treatment considerations with newly diagnosed older/elderly patients with chronic lymphocytic ...
KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML ...
Daniel Ermann, MD, highlights 6.5-year follow-up data for zanubrutinib from the phase 3 SEQUOIA trial, which compared the BTK ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results